b'IMBRUVICA (ibrutinib)IMBRUVICA (ibrutinib) Table 1: Non-Hematologic Adverse Reactions in10% of Patients Table 3: Adverse Reactions Reported in10% of Patients in the IMBRUVICA with CLL/SLL (N=51) in Study 1102 Treated Arm in Patients with CLL/SLL in RESONATE (continued)AllGrade 3 orIMBRUVICA OfatumumabGradesHigher (%) (N=195) (N=191)Body System Adverse Reaction (%) AllGrade 3AllGrade 3 GastrointestinalDiarrhea 59 4 Body System Grades or 4 Grades or 4disorders Constipation 22 2 Adverse Reaction (%) (%) (%) (%)Nausea 20 2 Musculoskeletal and Stomatitis 20 0 connective tissue disordersVomiting 18 2 Musculoskeletal pain* 28 2 18 1Abdominal pain 14 0Dyspepsia 12 0 Arthralgia 17 1 7 0Skin andBruising51 2 Muscle spasms 13 0 8 0subcutaneous tissueRash25 0 Skin and subcutaneous tissue disorders Petechiae 16 0 disordersInfections andUpper respiratoryRash* 24 3 13 0infestations tract infection 47 2 Petechiae 14 0 1 0Sinusitis 22 6 Bruising* 12 0 1 0Skin infection 16 6Pneumonia 12 10 General disorders and Urinary tract12 2 administration site conditionsinfection Pyrexia 24 2 15 2General disorders andFatigue 33 6 Respiratory, thoracic and administration sitePyrexia24 2 mediastinal disordersconditions Peripheral edema 22 0 Cough 19 0 23 1Asthenia 14 6 Dyspnea 12 2 10 1Chills 12 0Musculoskeletal andMusculoskeletal pain 25 6 Infections and infestationsconnective tissueArthralgia 24 0 Upper respiratory tract16 1 11 2disorders Muscle spasms 18 2 infectionRespiratory, thoracicCough 22 0 Pneumonia* 15 12 13 10and mediastinalOropharyngeal pain 14 0 Sinusitis* 11 1 6 0disorders Dyspnea 12 0 Urinary tract infection 10 4 5 1Nervous systemDizziness 20 0 Nervous system disordersdisorders Headache 18 2Vascular disorders Hypertension 16 8 Headache 14 1 6 0Metabolism andDecreased appetite 16 2 Dizziness 11 0 5 0nutrition disorders Injury, poisoning and Neoplasms benign,Second malignancies 10 2 procedural complicationsmalignant, unspecified Contusion 11 0 3 0 One patient death due to histiocytic sarcoma. Eye disordersVision blurred 10 0 3 0Table 2: Treatment-Emergent* Hematologic Laboratory AbnormalitiesThe body system and individual ADR terms are sorted in descending frequency in Patients with CLL/SLL (N=51) in Study 1102 order in the IMBRUVICA arm.Percent of Patients (N=51) * Includes multiple ADR termsAll Grades (%) Grade 3 or 4 (%)Includes 3 events of pneumonia with fatal outcome in each arm, and 1 event Platelets decreased 69 12 of pyrexia and upper respiratory tract infection with a fatal outcome in the ofatumumab arm. Neutrophils decreased 53 26Hemoglobin decreased 43 0 Table 4: Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with CLL/SLL in RESONATE* Based on laboratory measurements per IWCLL criteria and adverse reactions. IMBRUVICA OfatumumabTreatment-emergent Grade 4 thrombocytopenia (8%) and neutropenia (12%)(N=195) (N=191)occurred in patients.RESONATE:AdversereactionsandlaboratoryabnormalitiesdescribedAllGrade AllGradebelow in Tables 3 and 4 reflect exposure to IMBRUVICA with a medianGrades 3 or 4 Grades 3 or 4duration of 8.6 months and exposure to ofatumumab with a median of (%) (%) (%) (%)5.3 months in RESONATE in patients with previously treated CLL/SLL. Neutrophils decreased 51 23 57 26Table 3: Adverse Reactions Reported in10% of Patients in the IMBRUVICAPlatelets decreased 52 5 45 10Treated Arm in Patients with CLL/SLL in RESONATE Hemoglobin decreased 36 0 21 0IMBRUVICA Ofatumumab Treatment-emergent Grade 4 thrombocytopenia (2% in the IMBRUVICA arm (N=195) (N=191) vs 3% in the ofatumumab arm) and neutropenia (8% in the IMBRUVICA arm AllGrade 3AllGrade 3vs 8% in the ofatumumab arm) occurred in patients.Body System Grades or HigherGrades or Higher Adverse Reaction (%) (%) (%) (%) RESONATE-2:Adversereactionsandlaboratoryabnormalitiesdescribed Gastrointestinal disorders below in Tables 5 and 6 reflect exposure to IMBRUVICA with a median Diarrhea 48 4 18 2 duration of 17.4 months. The median exposure to chlorambucil was 7.1 months Nausea 26 2 18 0 in RESONATE-2.Stomatitis* 17 1 6 1Constipation 15 0 9 0Vomiting 14 0 6 1'